Introduction
A thyroid nodule is a frequently observed health problem. Thyroid nodules can be detected in 4% of the population by palpation and in up to 67% by ultrasonography (1) . Thyroid nodules are clinically crucial, as they have 5% to 10% probability of thyroid cancer (2) . A clinical approach to thyroid nodules aims at detecting cancerous nodules. The simplest and safest method to screen thyroid cancer is thyroid fine-needle aspiration biopsy (TFNAB; 3). It is recommended that benign nodules diagnosed by TFNAB should be followed up with physical examination and thyroid ultrasonography (3) . One of the most crucial criteria to be assessed during follow-up is the nodule growth. Rebiopsy is recommended for a growing nodule, which was initially benign (3) . However, studies have shown that benign nodules can also grow in their natural course (4) (5) (6) . There is no consensus about the "growth" criteria of thyroid nodules. Several criteria were used to establish the nodule "growth" (>50% increase in the maximal dimension of the nodule, >15% increase in the nodule volume, >30% increase in the nodule volume, etc. (7) . American Thyroid Association (ATA) has defined a 20% increase in at least two nodule dimensions with a minimal increase of 2 mm as an acceptable growth criterion (3). However, till date, no evidence exists that cancer risk increases in benign nodules growing at follow-up. This study aimed to compare the TFNAB results of the growing nodules, which had initially benign cytology, with non-growing nodules. We used two different growth criteria (i.e., at least 50% increase in the nodule maximal diameter and 20% increase in at least two nodule dimensions with a minimal increase of 2 mm) to detect whether the cancer risk of nodules growing at follow-up increases compared with the ones that do not grow.
Material and Methods
We retrospectively reviewed all results of ultrasonography-guided fine-needle aspiration biopsies performed at Dokuz Eylül University Hospital between January 2006 and June 2009. We recorded nodules that had repeated biopsies. Age, sex, radiation history to the neck, additional malignancy history, thyroid surgery history, familial history, and thyrotrophin stimulating hormone (TSH) level of the patient and the dimensions of the nodules were recorded. The nodules which had repeated biopsies were classified as growing and non-growing. Growth classification and evaluation have been performed separately according to two different criteria (at least 50% increase in the nodule maximal diameter and 20% increase in at least two nodule dimensions with a minimal increase of 2 mm), as no consensus exists about the exact growth criteria of thyroid nodules. The biopsy results were classified as benign, intermediate, or malign. Nodules that are Thy 2-3-4 according to Bethesda classification were classified as intermediate. The existence of surgical intervention toward the nodule after the second fine-needle aspiration biopsy was ascertained. If there was any surgical intervention, we recorded the pathological diagnosis of the nodule. The study protocol was approved by the local ethics committee. Statistical analysis was performed using SPSS V15.0, SPSS Inc., Chicago. Nominal data were evaluated using chi-square test; continuous variables were assessed using independent sample's t-test or Mann-Whitney U test. Logistic regression analysis was performed for assessing the independent impact of a specific variable on other parameters.
Results
We retrospectively analyzed 4217 thyroid nodule biopsies from 3202 patients at Dokuz Eylül University Hospital between January 2006 and June 2009 ( Figure 1 ). The general characteristics of the nodules are summarized in Table 1 . Out of the initial benign nodules (3509), 117 nodules that had repeated biopsy were included in the statistical analysis. There were 47 growing and 70 non-growing nodules using the growth criteria of 20% increase in at least two nodule dimensions with a minimal increase of 2 mm (Group 1); and there were 21 growing and 96 non-growing nodules using the growth criteria of at least 50% increase in the nodule maximal diameter (Group 2).
Group 1
No difference was observed in terms of age, TSH, and the initial maximal diameter of the nodule between growing and non-growing groups (Table  2) . Follow-up time was longer in the growing group than the non-growing group (2.76 ±1.30 years vs. 2.13 ±1.33 years, p = 0.050). In addition, no difference was observed in the cytological results of rebiopsies between the two -20 groups (p=0.70). Two nodules with non-benign cytology in the growing group were operated; both nodules were defined as papillary thyroid cancer (PTC). A total of 5 nodules out of 45 nodules with benign cytology in the growing group were operated; 3 of these nodules were defined as PTC. There were five nodules with intermediate cytology in the non-growing group; three of these nodules were operated, and two PTC and one benign nodule were established ( Table 3 ). All of the five nodules with benign cytology in the non-growing group had benign pathology after surgery.
In the linear regression model including age, sex, TSH level, and follow-up period, the follow-up period was 1.5 times high in the growing nodules (Table 4) .
Group 2
No difference in terms of age and TSH levels was observed between the growing and non-growing groups. The non-growing group had higher initial diameter than the growing group (Table 2 ). In addition, no difference was observed in terms of cytological results between the growing and nongrowing groups (p=0.999). In both groups, malign cytology result was not found. After the surgical excision of the nodule with intermediate cytology in the growing group, PTC was found. Out of the 20 growing nodules, which had benign cytology, three were operated and all of them had benign pathology. Furthermore, four nodules with intermediate cytology were excised surgically in the non-growing group, although PTC was detected in three of them (Table 3 ). In addition, seven of the non-growing nodules with benign cytology were operated, although three of them had PTC. When the data were evaluated with linear regression analysis, age, sex, initial TSH level, and follow-up period were not associated with nodules, which grow according to Group 2 criteria ( 
Discussion
In this study, we retrospectively examined the rebiopsies of thyroid nodules. Considering the two different growth criteria, we did not find an increased rate of malignancy in growing, initially benign nodules. The natural course of benign thyroid nodules is not completely understood. Although the growth of the benign nodule can be attributed to its natural course, most guidelines recommended rebiopsy to exclude malignancy in growing nodules (3). There were different growth criteria used for defining the nodule "growth." The rate of nodule growth differed when different growth criteria were used. for ≥50% change in the maximal diameter of the nodule; 7). Lim et al. reported that 11.8% and 9.4% of benign nodules grew using ≥50% increase in volume and ≥20% increase in at least two nodule dimensions with a minimal increase of 2 mm as a cut-off value, respectively (8) .
ATA recommended the rebiopsy of initially benign nodules if ≥20% increase was observed in at least two nodule dimensions with a minimal increase of 2 mm (3). Durante et al. reported that 15.4% (n=153) of the benign nodules grew using the ATA criteria (9) . Only two malignancies were detected from these nodules after second TFNAB. Rosario et al. reported the rebiopsy results of the initial benign nodules (10) . Out of 86 growing nodules (using ATA criteria), only three malignancies (3.5%) were detected after the second biopsy. In addition, Kim et al. reported a growth rate of 21.1% considering the criteria of 50% change in the nodule volume (11) . Moreover, they found only one malignancy among 172 growing nodules. The results of all these studies suggested that a proportion of benign nodules grow over time and the malignancy rate of these growing nodules in follow-up is very low. In a recent study, malign nodules were found more likely to grow more than 2 mm/year compared with benign nodules (12) . As a limited number of patients had final pathology in our study, no difference was observed between benign and malign nodules in terms of nodule growth speed. In addition, the follow-up time for growing nodules was longer than that for nongrowing nodules in Group 1. No data exist in the literature comparing the follow-up time and growth; therefore, additional studies are required to interpret this finding. We have found intermediate cytological results in growing and non-growing nodules during followup. The reason for changing the cytological characteristics of the nodules may be the false negative rate of the initial TFNAB rather than that the growth in follow-up increases the malignancy risk. As in a study in which growth has not been used as a criterion and the rebiopsies of benign nodules during follow-up have been examined, rebiopsies in 13.2% of benign nodules showed intermediate or malign cytology (13) . Similarly, in another study including the rebiopsies of benign nodules with suspicious ultrasonographic features, in 17.4% of them, suspicious cytology was found (14) . Therefore, in some studies, TFNAB is recommended for benign thyroid nodules in follow-up (15) . We faced various limitations during our study. First, a retrospective approach weakens the strength of the study. In this study, we used the biopsies from non-growing nodules as a control group. However, data were not available indicating the reason for taking a biopsy from the nongrowing nodules during follow-up. Repeated biopsy may have been taken from a group with Table 5 . Factors predicting at least 50% increase in nodule maximal diameter.
high clinical cancer suspicion even there was no dimensional growth. Therefore, the control group may be a group with high risk. Intermediate risk category is a very heterogeneous group, and possible discordance between the cytologists is another limitation.
Conclusions and Recommendations
The most outstanding clinical importance of thyroid nodule is a cancer risk. In this study, two different growth criteria were used, and it was observed that the cancer risk of growing benign nodules was not higher than the non-growing ones. It is necessary that these findings are supported by broad and prospective studies. Source of Finance: During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.
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